SubsidieMeestersA new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Projectdetails
Introduction
Ischemic Heart Disease kills more than 1.7M people/year in the EU, the vast majority via a heart attack (Myocardial Infarction - MI). Heart failure (HF) is the major cause of death after MI with a prevalence of >26M individuals globally.
Current Treatment Challenges
While current treatment involving restoration of blood flow to the heart saves the MI patient’s life, it also causes additional damage to the heart through an inflammatory reaction known as reperfusion injury.
ResoTher's Drug Candidate
ResoTher’s leading drug candidate, RTP-026, is an immunomodulating therapeutic aimed at resolving inflammation triggered during MI. This approach is intended to:
- Reduce damage to the heart
- Significantly decrease the risk of HF and death
Pre-clinical data suggests RTP-026 could reduce post-MI HF by >20%.
Clinical Studies
A Phase I study has been conducted to determine the safety and tolerability of RTP-026 in Healthy Volunteers. With the EIC, we aim to validate RTP-026's clinical effectiveness through:
- A Phase IIa patient proof of principle study
- A Phase IIb proof of concept study
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.770.625 |
Tijdlijn
| Startdatum | 1-2-2024 |
| Einddatum | 31-1-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- RESOTHER PHARMA A/Spenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Transcatheter Ventricular Repair Device for treatment of Heart Failure PatientsCardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing. | EIC Accelerator | € 2.500.000 | 2022 | Details |
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market. | EIC Accelerator | € 2.498.816 | 2024 | Details |
Saving patients from severe heart failureThe ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Commercialising a smart cardiac implant platform for the treatment of chronic cardiovascular diseaseAuriGen's platform aims to reduce chronic cardiac disease deaths and costs in Europe by providing advanced, multi-functional cardiac devices for effective, minimally invasive patient treatment. | EIC Accelerator | € 2.499.999 | 2023 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients
Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)
The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market.
Saving patients from severe heart failure
The ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials.
Commercialising a smart cardiac implant platform for the treatment of chronic cardiovascular disease
AuriGen's platform aims to reduce chronic cardiac disease deaths and costs in Europe by providing advanced, multi-functional cardiac devices for effective, minimally invasive patient treatment.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Molecular Imaging to Guide Repair and Advance Therapy: Targeting the inflammation-fibrosis axis in ischemic heart disease and remote organsMIGRATe aims to optimize imaging-guided, molecular-targeted therapies for improved cardiac repair post-myocardial infarction while assessing inter-organ communication effects. | ERC Consolid... | € 1.933.148 | 2025 | Details |
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial InfarctionTargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation. | EIC Pathfinder | € 3.999.840 | 2023 | Details |
Optimize risk prediction after myocardial infarction through artificial intelligence and multidimensional evaluationThis project aims to enhance myocardial infarction risk prediction by integrating data from wearable devices, biomarkers, and AI to identify novel risk factors for improved clinical decision-making. | ERC Starting... | € 1.405.894 | 2024 | Details |
Harnessing Novel Micropeptides in Cardiomyocytes to promote Cardiac RegenerationNovel.CaRe aims to enhance cardiac regeneration post-myocardial infarction by using micropeptides to stimulate cardiomyocyte proliferation and maturation through innovative gene therapy approaches. | ERC Starting... | € 1.592.281 | 2024 | Details |
Molecular Imaging to Guide Repair and Advance Therapy: Targeting the inflammation-fibrosis axis in ischemic heart disease and remote organs
MIGRATe aims to optimize imaging-guided, molecular-targeted therapies for improved cardiac repair post-myocardial infarction while assessing inter-organ communication effects.
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarction
TargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation.
Optimize risk prediction after myocardial infarction through artificial intelligence and multidimensional evaluation
This project aims to enhance myocardial infarction risk prediction by integrating data from wearable devices, biomarkers, and AI to identify novel risk factors for improved clinical decision-making.
Harnessing Novel Micropeptides in Cardiomyocytes to promote Cardiac Regeneration
Novel.CaRe aims to enhance cardiac regeneration post-myocardial infarction by using micropeptides to stimulate cardiomyocyte proliferation and maturation through innovative gene therapy approaches.